Navigation Links
BioElectronics' Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
Date:4/25/2012

FREDERICK, Md., April 25, 2012 /PRNewswire/ -- BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, today announced the results of a customer survey.  The results indicate that patients using BIEL's ActiPatch® therapy report a five-fold greater pain reduction than those using non-steroidal anti-inflammatory products such as ibuprofen and aspirin.

ActiPatch Therapy, which uses pulsed shortwave therapy based on large expensive machines used in clinics and hospitals, was most frequently used to treat lower back pain by participants in the survey.  Lower back pain is a major health problem in western industrialized countries and a major cause of medical expenses and disablement.

"The most widely used OTC drugs have a significant number of side effects, are minimally effective and have only short-term symptomatic relief," said Ian Rawe, Ph.D., BioElectronics Director of Clinical Research. "In comparison, ActiPatch users who participated in the survey had a five-fold greater pain reduction than persons using non-steroidal anti-inflammatory drugs, based on a comparison to published clinical data. Additionally, with ActiPatch's all-day safe pain relief, people can resume their normal daily activities."

"We are very pleased by the results of our consumer survey, which confirms our clinical studies in which ActiPatch users as compared to users of OTC pain medications, have greater pain relief and an improved quality of life," Dr. Rawe said. "An increased consumer awareness of the dangers of overuse of oral analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs has significantly altered the competitive landscape for pain management therapeutics. There is significant need for an improved efficacy, competitively priced over-the-counter therapeutic agent with no side-effects."

Results of the survey, which also show that patients would recommend ActiPatch® to a friend and would themselves purchase another ActiPatch® if the need arose, can be viewed at: www.bielcorp.com/survey.

About BioElectronics Corporation

BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care method to reduce soft tissue pain and swelling. For more information, please visit www.bielcorp.com.

Contact:  E & E Communications
Paul Knopick
(949) 707-5365


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery
2. BioElectronics Corporation to Webcast, Live, at RetailInvestorConferences.com on October 6th
3. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
4. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
5. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
6. BioElectronics Announces Major Clinical Trials
7. KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard
8. Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation
9. New Survey: Walgreens Customers Flock to Independent Pharmacies
10. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
11. Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
(Date:12/6/2016)... Dec. 6, 2016 Homozygous Familial ... Summary Global Markets Direct,s latest ... Familial Hypercholesterolemia (HoFH) – Pipeline Review, H2 ... Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline landscape. ... disorder which is caused due to mutation ...
(Date:12/6/2016)... 6, 2016   AlloSource , one of ... skin and soft-tissue allografts for use in surgical ... Manager, for being named to the Board of ... Award by the Commerce Department,s National Institute of ... to process excellence. The Baldrige Award is the ...
Breaking Medicine Technology:
(Date:12/7/2016)... (PRWEB) , ... December 07, ... ... Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers ... Plus substantially enhances the WellnessPro platform by expanding the treatment modalities available ...
(Date:12/7/2016)... ... ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration depicting the ... “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy Engestrom, a ... Nancy attributes her patriotic nature to her WWII veteran father. She says, “I ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/7/2016)... ... 2016 , ... NuevaCare, a leading home care agency based in San Mateo ... pages as part of its ambitious website relaunch. As Bay Area clients scramble to ... agencies serving their city. The new site has several key city-specific pages to address ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... collaborate in developing a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). ... available in South Korea for emergency deployment in the event of a future ...
Breaking Medicine News(10 mins):